Sapio Sciences, a leading, high growth lab informatics platform company, has been sold Global Healthcare Opportunities, or GHO Capital Partners, a European specialist investor in global healthcare. Based in York, Pennsylvania, Sapio is a unique, world-class integrated lab informatics platform helping to transform and accelerate life science R&D for international biopharmaceutical companies, CROs and clinical diagnostic labs. Sapio serves a blue-chip customer base throughout the United States with additional footholds in Europe and Japan. The Company is strongly positioned to address an international, high growth market demanding new data-driven and fit for purpose AI assisted lab informatics technologies.
Founded in 2004 by Chief Scientist and CEO Kevin Cramer, Sapio has established a best in class, highly scalable technology solution addressing the Laboratory Information Management (LIMS), Electronic Laboratory Notebooks (ELN) and Scientific Data Management (SDMS) markets with its unified low-code, no-code platform. Sapio’s clinical LIMS uniquely offers complete end to end operational support for molecular diagnostic labs including a physician portal for test ordering, kit management, sample shipment and accessioning, order transcription to lab processing and patient reporting in a seamless solution. The business is optimally positioned in a high growth market where many incumbent solutions are not fit for purpose. This is particularly important in an increasingly complex drug discovery and development landscape in research areas such as bioanalysis, genomic sequencing utilizing AI/ML capabilities, as well as expanding into the GMP market.
EC M&A acted as exclusive financial advisor to Sapio in this transaction.
